Category - News

Developments

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...

October 13, 2023

Developments

Anixa Biosciences completes first cohort in ovarian cancer CAR-T clinical trial

Anixa Biosciences (NASDAQ:ANIX), in partnership with Moffitt Cancer Center, completed treatment of the first patient cohort in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy...

October 13, 2023

Developments

Sigyn Therapeutics submits international patent application for ChemoPrep and ChemoPure

Sigyn Therapeutics (OTCQB:SIGY) submitted a Patent Cooperation Treaty (PCT) application for the technologies it is developing to enhance the clinical benefit of chemotherapeutic drugs. Chemotherapy is the most commonly...

October 5, 2023

Developments

Anixa’s breast cancer vaccine featured in Yahoo Life news

Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine was featured in an Oct. 3 article in Yahoo Life news. The article introduces Ohioan Jennifer Davis as the first person in the world to receive a breast cancer...

October 4, 2023

Developments

Hepion in $5-million registered direct offering

Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase of 980,393 shares of the company at a purchase price of $5.10 per share...

September 29, 2023

Developments

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

PharmaJet partner, Scancell, reported positive data from the first phase of a Phase 2 clinical trial evaluating PharmaJet’s needle-free vaccine delivery system for treatment of advanced melanoma. The Phase 2 study’s...

September 28, 2023

Executive Moves

Mati promotes Chris Muller to COO

Closely-held Mati Therapeutics named Chris Muller as COO, effective immediately. Most recently Mati’s CCO, Mr. Muller’s expanded responsibilities include overseeing all operating activities; and preparing for and...

September 28, 2023

Developments

Profound Medical gets FDA 510(k) clearance for first TULSA-PRO AI module, Thermal Boost

Profound Medical (NASDAQ:PROF; TSX:PRN) received FDA 510(k) clearance for its Thermal Boost module for use in conjunction with TULSA-PRO. Thermal Boost enables predictable, customized ablation at the prostate capsule...

September 25, 2023

Markets

Spheric BioCantor starts Solid at OW; PT $5

Cantor Fitzgerald launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “overweight” rating and 12-month price target of $5. The stock closed at $2.76 on Sept. 22. Solid is using its gene therapy platform to...

September 25, 2023

Executive Moves

Aurinia appoints Hepion’s Dr. Robert T. Foster to board

Aurinia Pharmaceuticals (NASDAQ:AUPH) appointed Dr. Robert T. Foster, CEO of Hepion Pharmaceuticals, to its board. “As the doctor who discovered voclosporin, and Aurinia’s founder, [Dr. Foster] has a wealth of...

September 21, 2023

Category - News

Subscribe